However, another trial, BEVERLY-1 (ClinicalTrials.gov Identifier: NCT00820547; Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer; Table 1), indicated that the addition of bevacizumab to neoadjuvant and adjuvant chemotherapy conferred no clinical benefit to non-metastatic HER2− IBC patients [107]. The gene discussed is ERBB2; the disease is breast cancer.